1 |
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [J]. JAMA, 2016, 315(8): 801-810.
|
2 |
Petrosillo N, Taglietti F, Granata G. Treatment options for Colistin resistant Klebsiella pneumoniae: present and future [J]. Journal of Clinical Medicine, 2019, 8(7): 934.
|
3 |
Sy CL, Chen PY, Cheng CW, et al. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms [J]. J Microbiol Immunol Infect, 2022, 55(3): 359-386.
|
4 |
Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin [J]. Clin Microbiol Rev, 2016, 29(2): 321-347.
|
5 |
Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) [J]. Pharmacotherapy, 2019, 39(1): 10-39.
|
6 |
Gil-Perotin S, Ramirez P, Marti V, et al. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept [J]. Crit Care, 2012, 16(3): R93.
|
7 |
Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [J]. Clin Infect Dis, 2016, 63(5): e61-e111.
|
8 |
Almangour TA, Garcia E, Zhou Q, et al. Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes [J]. Int J Antimicrob Agents, 2021, 57(6): 106328.
|
9 |
Liu X, Huang C, Bergen PJ, et al. Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society [J]. J Zhejiang Univ Sci B, 2023, 24(2): 130-142.
|